A consistent safety profile and sustained efficacy were observed in patients with moderate to severe plaque psoriasis.
The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback